Ferric Carboxymaltose

2009/01/01 by Katherine A. Lyseng-Williamson, Katherine A. Lyseng‐Williamson, Gillian M. Keating · 26 citations
Medicine · #Iron Metabolism and Disorders #Hemoglobinopathies and Related Disorders #Erythropoietin and Anemia Treatment

paper · doi:10.2165/00003495-200969060-00007

Cited by

• Iron metabolism and iron supplementation in cancer patients
• Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. [europepmc]
• Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. [europepmc]
• Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study. [europepmc]
• Treatment of Iron Deficiency with or without Anaemia with Intravenous Ferric Carboxymaltose in Gynaecological Practices - A Non-Interventional Study. [europepmc]
• Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases. [europepmc]
• Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: study protocol for a randomised controlled trial. [europepmc]
• Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations. [europepmc]
• Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations. [europepmc]
• Iron metabolism and iron supplementation in cancer patients. [europepmc]
• Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. [europepmc]
• The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease. [europepmc]
• Clinical iron deficiency disturbs normal human responses to hypoxia. [europepmc]
• Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia. [europepmc]
• A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Ferric Carboxymaltose in Iron-Deficient Patients with Fibromyalgia. [europepmc]
• Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. [europepmc]
• Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron. [europepmc]
• Camouflaging Nanoparticles for Ratiometric Delivery of Therapeutic Combinations. [europepmc]
• Therapeutic Nanoparticles and Their Targeted Delivery Applications. [europepmc]
• Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up. [europepmc]
• Payment incentives and the use of higher-cost drugs: a retrospective cohort analysis of intravenous iron in the Medicare population. [europepmc]
• Efficacy and Safety of Intravenous Ferric Carboxymaltose in Patients with Postoperative Anemia Following Same-Day Bilateral Total Knee Arthroplasty: A Randomized Controlled Trial. [europepmc]
• Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia. [europepmc]
• Efficacy and Safety of Ferric Carboxymaltose in the Management of Iron Deficiency Anemia: A Multi-Center Real-World Study from India. [europepmc]
• IV iron formulations and use in adults. [europepmc]
• A meta-analysis of ferric carboxymaltose versus other intravenous iron preparations for the management of iron deficiency anemia during pregnancy. [europepmc]